IL207641A0 - Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease - Google Patents

Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease

Info

Publication number
IL207641A0
IL207641A0 IL207641A IL20764110A IL207641A0 IL 207641 A0 IL207641 A0 IL 207641A0 IL 207641 A IL207641 A IL 207641A IL 20764110 A IL20764110 A IL 20764110A IL 207641 A0 IL207641 A0 IL 207641A0
Authority
IL
Israel
Prior art keywords
compositions
nucleic acids
acids encoding
ocular disease
treating ocular
Prior art date
Application number
IL207641A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL207641A0 publication Critical patent/IL207641A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL207641A 2008-02-20 2010-08-16 Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease IL207641A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3007208P 2008-02-20 2008-02-20
US3454608P 2008-03-07 2008-03-07
US5663208P 2008-05-28 2008-05-28
PCT/US2009/034709 WO2009105669A2 (en) 2008-02-20 2009-02-20 Angiogenesis inhibition

Publications (1)

Publication Number Publication Date
IL207641A0 true IL207641A0 (en) 2010-12-30

Family

ID=40986215

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207641A IL207641A0 (en) 2008-02-20 2010-08-16 Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease

Country Status (5)

Country Link
JP (1) JP2011512417A (ja)
CN (1) CN101951925A (ja)
BR (1) BRPI0908496A2 (ja)
IL (1) IL207641A0 (ja)
WO (1) WO2009105669A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6157461B2 (ja) * 2011-06-30 2017-07-05 ジェンザイム・コーポレーション Ｔ細胞活性化の阻害剤
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
LT2968461T (lt) * 2013-03-13 2022-12-27 Genzyme Corporation Sulieti baltymai, apimantys pdgf ir vegf surišančius fragmentus, ir jų panaudojimo būdai
CN106163573A (zh) * 2014-02-06 2016-11-23 建新公司 用于治疗和预防黄斑变性的组合物及方法
AU2015231439B2 (en) 2014-03-17 2019-11-14 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
SG11201707063TA (en) 2015-03-02 2017-09-28 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
CN108348572B (zh) 2015-03-31 2021-06-29 日东制药株式会社 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
GB201806333D0 (en) * 2018-04-18 2018-05-30 Glaxosmithkline Ip Dev Ltd Parvovirus vector production
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536274A (en) * 2002-05-01 2008-04-30 Univ Florida Improved rAAV expression systems for genetic modification of specific capsid proteins
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte

Also Published As

Publication number Publication date
WO2009105669A3 (en) 2009-12-17
WO2009105669A2 (en) 2009-08-27
BRPI0908496A2 (pt) 2019-01-15
JP2011512417A (ja) 2011-04-21
CN101951925A (zh) 2011-01-19

Similar Documents

Publication Publication Date Title
IL207641A0 (en) Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease
IL254498B (en) Peptidomimetic macrocyclic composition for use in the treatment of diseases
IL217540A (en) An oral preparation for use in oral disinfection or in the treatment of oral diseases
IL229059A (en) 9pcsk antagonists
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
HK1207576A1 (en) Vla-1 antagonist for use in treating stroke vla-1
IL207892A0 (en) Agent for treating disease
HK1151533A1 (zh) 種治療疾病的試劑
ZA201007215B (en) Agent for treating disease
EP2452668A4 (en) EMULSIFIED COMPOSITION
PL2346356T5 (pl) Płynna kompozycja białkowa o wysokiej zawartości tłuszczu
PL2023945T3 (pl) Kompozycja poprawiająca zdrowie oczu
ZA201104062B (en) Compositions and methods for controlling disease in animals
PL2315773T3 (pl) Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
EP2350042A4 (en) NEW THIOPHIC COMPOUNDS FOR THERAPEUTIC PURPOSES
HK1169596A1 (en) Emulsified cosmetic composition
HK1154797A1 (en) Composition for treating disease
EP2262365A4 (en) USE OF '-THIO-2'-DEOXYNUCLEOSIDES AS ACTIVE AGENTS AGAINST ORTHOPOXVIRUS
EP2337571A4 (en) METHOD OF DETERMINING THE BIOACTIVITY OF TGF-BETA IN A COMPOSITION
EP2320931A4 (en) COMPOSITIONS COMPRISING MG29 NUCLEIC ACIDS, POLYPEPTIDES AND ASSOCIATED METHODS OF USE
EP2354223A4 (en) NUCLEIC ACID DRUG TO TREAT AN ALLERGIC DISEASE
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
IL190579A (en) Playing @ Latin
HK1172547A1 (en) Activin-actrii antagonists for use in treating anemia -actrii
GB0910378D0 (en) Oil compositions for use in therapy